Literature DB >> 18049018

Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (1) Rationale for salt restriction and salt-restriction target level for the management of hypertension.

Yuhei Kawano1, Katsuyuki Ando, Hideo Matsuura, Takuya Tsuchihashi, Toshiro Fujita, Hirotsugu Ueshima.   

Abstract

Salt excess is well known to be involved in the pathophysiology of hypertension, and thus restriction of salt intake is widely recommended for management of the disease. Excessive salt intake induces blood pressure (BP)-dependent as well as -independent progression of cardiovascular disease. Although the human body is considered to be adapted to very low salt intake (0.5-3 g/day), restriction to such a low level of salt intake is extremely difficult to accomplish in developed countries. Significant BP reduction has been reported in large-scale clinical studies in which salt intake was decreased to less than 6 g/day, and the results of a meta-analysis have shown that systolic BP was reduced about 1 mmHg with every decrease in salt intake of 1 g/day in hypertensive subjects. Current guidelines for the treatment of hypertension, including Japanese guidelines, recommend dietary salt reduction to 6 g/day or less in hypertensive patients. However, it appears to be fairly difficult to attain this target of salt intake, especially in Japan. There is thus a need for feasible and effective measures to attain this salt restriction target.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18049018     DOI: 10.1291/hypres.30.879

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  9 in total

1.  Current dietary salt intake of Japanese individuals assessed during health check-up.

Authors:  Akiko Toda; Yuko Ishizaka; Mizuki Tani; Minoru Yamakado
Journal:  Hypertens Res       Date:  2014-10-30       Impact factor: 3.872

Review 2.  Biochemical interaction of salt sensitivity: a key player for the development of essential hypertension.

Authors:  Imran Kazmi; Waleed Hassan Al-Maliki; Haider Ali; Fahad A Al-Abbasi
Journal:  Mol Cell Biochem       Date:  2020-10-18       Impact factor: 3.396

Review 3.  Functional foods for augmenting nitric oxide activity and reducing the risk for salt-induced hypertension and cardiovascular disease in Japan.

Authors:  Theodore W Kurtz; Stephen E DiCarlo; Michal Pravenec; R Curtis Morris
Journal:  J Cardiol       Date:  2018-03-12       Impact factor: 3.159

Review 4.  Healthy aging diets other than the Mediterranean: a focus on the Okinawan diet.

Authors:  Donald Craig Willcox; Giovanni Scapagnini; Bradley J Willcox
Journal:  Mech Ageing Dev       Date:  2014-01-21       Impact factor: 5.432

5.  Sodium intake in men and potassium intake in women determine the prevalence of metabolic syndrome in Japanese hypertensive patients: OMEGA Study.

Authors:  Tamio Teramoto; Ryuzo Kawamori; Shigeru Miyazaki; Satoshi Teramukai
Journal:  Hypertens Res       Date:  2011-06-09       Impact factor: 3.872

Review 6.  Systolic hypertension: an increasing clinical challenge in Asia.

Authors:  Jeong Bae Park; Kazuomi Kario; Ji-Guang Wang
Journal:  Hypertens Res       Date:  2014-12-11       Impact factor: 3.872

7.  The SONG (Salt intake and OrigiN from General foods) Study - A Large-scale Survey of the Eating Habits and Dietary Salt Intake in the Working-age Population.

Authors:  Yoshitaka Isaka; Toshiki Moriyama; Kiyomi Kanda
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

8.  Effects of disclosing hypothetical genetic test results for salt sensitivity on salt restriction behavior.

Authors:  Taro Takeshima; Masanobu Okayama; Masanori Harada; Ryusuke Ae; Eiji Kajii
Journal:  Int J Gen Med       Date:  2013-05-14

9.  The Nutritional Characteristics of the Hypotensive WASHOKU-modified DASH Diet: A Sub-analysis of the DASH-JUMP Study.

Authors:  Atsuko Kawamura; Katsuko Kajiya; Hiroko Kishi; Junko Inagaki; Makoto Mitarai; Hiroshi Oda; Seiji Umemoto; Sei Kobayashi
Journal:  Curr Hypertens Rev       Date:  2018
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.